Ibogaine and the Reinvention of Addiction Recovery w. Shayne Nyquvest and Jeremy Weate – Ep. 58



SUMMARY

The opioid crisis has created a pressing need for successful addiction treatments, especially as the majority of people who seek treatment are highly likely to relapse.

In today’s episode, we speak with Founder and Co-Chairman, Shayne Nyquvest and CEO, Jeremy Weate at Universal Ibogaine. Their company is aiming to address the opioid crisis and revolutionize the therapy industry by using ibogaine in addiction recovery.

“Psychiatry is a 19th-century profession without the tools. All they have is symptom maintenance. It’s an honour to be working on bringing psychiatry into the 21st century.” — Jeremy Weate [0:27:02]

To introduce the subject, Shayne shares a story about how someone close to him managed to recover from their addiction through ibogaine therapy. Jeremy talks about ibogaine’s unique ability to target neural receptors and help create ‘helper cells’ to refresh the brain and central nervous system. He then discusses its fascinating history, ranging from its ceremonial use in Gabon to its shadier applications by the CIA.

“With addiction recovery, Ibogaine is, in my opinion, something that can move the needle in an industry with a 95% failure rate.” — Shayne Nyquvest [0:03:54]

After providing further context on ibogaine, Shayne takes the lead in explaining the business model that they’re building out and the niche that Universal Ibogaine aims to fit in the marketplace. We talk about how they plan to finance the company, the clinical trials that they’re going through, and why Canada is the perfect country to be their base of operations. We also chat about the need to dispel fears around ibogaine and how the public needs to be educated about its benefits.

“This is a whole new industry that is going to require education because everyone wants to do psychedelics but they’re afraid of doing them.” — Shayne Nyquvest [0:18:19]

Based on Shayne’s extensive career in finance and brokering deals, we ask him to share his views on the state of the investment industry and he goes on to detail the differences between the marijuana sector and Universal Ibogaine’s business strategy.

There’s a lot of buzz around ibogaine. Listen to this episode to learn about this emerging and potentially game-changing industry. 

New Episodes Weekly

Key Points From This Episode:

  • Shayne talks about ibogaine’s remarkable ability to treat addiction.
  • The failures of the health system and how it’s created a cycle of addiction.
  • What ibogaine is, where it comes from, and its repairing effects on neural sensors.
  • France and America’s hidden history of using ibogaine and discovering its benefits.
  • Understanding the traditional approaches to treating addiction.
  • The state of the ibogaine industry and the need to dispel myths and negative associations.
  • Mapping the future of Universal Ibogaine and its business model.
  • How Shayne and Jeremy are financing their company.
  • The need to educate the public about the new ibogaine industry.
  • Clinical trial durations and why Universal Ibogaine is offering five-year warrants.
  • Shayne’s view of the brokerage industry and why you should avoid ETFs.
  • The marijuana sector versus the ibogaine market and how ibogaine has a greater connection to the mental health industry.
  • The role of Universal Ibogaine in bringing psychiatry into the 21st century.
  • Shayne shares his final thoughts on Universal Ibogaine and the emerging industry.

RELATED POSTS

New Episodes Weekly

Scroll to Top

LETS TALK

IR has changed and investor marketing is to blame.

Your message, materials, and approach have a material impact on the outcome of your investor engagements.

Let’s connect to see how you can take back in control.